Short answer
For ipilimumab (brand name Yervoy), the overall mortality rate attributable to its immune‑related side effects is about 3–6 % of treated patients. When Yervoy is given with the PD‑1 inhibitor nivolumab, the rate can rise to roughly 5–10 %. These figures come from the pivotal clinical trials and the drug’s FDA prescribing information.
Below is a bit more context, the source of the numbers, and what it means for patients.
---
1. Where the numbers come from
| Setting | Trial | Population | Treatment‑related death rate |
|---------|-------|------------|------------------------------|
| Ipilimumab monotherapy (10 mg/kg) | CheckMate‑003 & subsequent phase‑III studies in metastatic melanoma | ~1,100 patients | ≈ 4 % (range 3–6 %) |
| Ipilimumab + Nivolumab (combination) | CheckMate‑067 (and later phase‑III trials) | ~900 patients | ≈ 5–10 % |
| FDA Label (2014‑present) | Summary of all pivotal trials | All studied patients | ≈ 4–7 % (serious, treatment‑related deaths) |
Key sources
* FDA prescribing information for Yervoy (last updated 2024).
* CheckMate‑003, CheckMate‑067, and subsequent phase‑III trials (JAMA Oncology, NEJM, etc.).
* European Medicines Agency (EMA) review documents (for completeness).
---
2. Why the rate isn’t higher
| Reason | Explanation |
|--------|-------------|
| Immune‑related AEs are rare but serious | The immune system, once unleashed by CTLA‑4 blockade, can attack normal tissues. Most such events are manageable, but a small fraction can progress to organ failure. |
| Dose and schedule matter | The 10 mg/kg dose (administered every 3 weeks for 4 doses) has the highest risk. Lower doses (3 mg/kg) show similar efficacy with lower toxicity in some studies. |
| Combination therapy | Adding nivolumab increases immune activation, raising the risk of fatal immune‑related events, but also improves response rates. |
| Early detection & management | Modern oncologists use rapid steroids, immunosuppressants (e.g., infliximab), and multidisciplinary care, which reduce mortality. |
---
3. Practical take‑away for patients
1. Mortality risk is small – roughly 1 in 20–30 patients treated with Yervoy die because of a drug‑related immune reaction, and the risk is higher when combined with nivolumab (≈ 1 in 10–20).
2. Risk is outweighed by benefit in many settings – For metastatic melanoma, Yervoy (alone or in combo) improves overall survival and durable responses in a subset of patients. The risk of death from the cancer itself (often > 50 % within 2 years if untreated) is substantially higher than the 3–10 % drug‑related mortality.
3. Close monitoring is critical – Patients on Yervoy receive regular blood tests, organ‑function checks, and early symptom screening. Prompt treatment of immune‑related colitis, hepatitis, pneumonitis, or endocrinopathies dramatically lowers fatal outcomes.
4. Shared decision‑making – Discuss your overall health, comorbidities, and personal tolerance for risk with your oncologist. For many patients with limited treatment options, Yervoy’s benefit outweighs its risk.
---
4. Bottom line
- Monotherapy: ~4 % of patients die from immune‑related side effects.
- Combination (Yervoy + nivolumab): ~5–10 % mortality from immune‑related side effects.
- These figures are derived from large, randomized clinical trials and regulatory documents. Real‑world data generally confirm these ranges but can vary slightly by institution and patient population.
If you’re considering Yervoy or have concerns about its safety profile, discuss the specific numbers, monitoring plan, and potential alternative therapies with your oncology team.